Brief: Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data For Its Oral Covid-19 Vaccine

Oramed Pharmaceuticals

07/10/2022 14:26

Oct 7 (Reuters) - Oramed Pharmaceuticals Inc  ORMP.O :
    * ORAMED SUBSIDIARY ORAVAX REPORTS POSITIVE PRELIMINARY
PHASE 1
DATA FOR ITS ORAL COVID-19 VACCINE
    * ORAMED PHARMACEUTICALS INC - PRIMARY AND SECONDARY
ENDPOINTS OF
SAFETY AND IMMUNOGENICITY MET
    * ORAMED PHARMACEUTICALS INC - NO SAFETY ISSUES OBSERVED,
INCLUDING MILD SYMPTOMS IN PRELIMINARY PHASE 1 TRIAL RESULTS
    * ORAMED PHARMACEUTICALS INC - ORAL VACCINE ELICITED
POTENTIALLY
PROTECTIVE IGG RESPONSE WITH SIGNIFICANT SEROCONVERSION FROM
BASELINE

Source text for Eikon:  ID:nPn6T1MCpa 
Further company coverage:  ORMP.O 
 ((Reuters.Briefs@thomsonreuters.com;;))